A potential role for alterations of zinc and zinc transport proteins in the progression of alzheimer's disease

Journal of Alzheimer's Disease

Volumn 16, Issue 3, 2009, Pages 471-483

  Lovell, Mark A ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b 135 Sanders Brown Building ^*  (United States)

Author keywords

Amyloid ; Early Alzheimer's disease; Mild cognitive impairment; Zinc; Zinc transport proteins

Indexed keywords

8 QUINOLINOL; AMYLOID BETA PROTEIN; CLIOQUINOL; ZINC; ZINC TRANSPORTER; CARRIER PROTEIN; ZINC BINDING PROTEIN; ZINC-BINDING PROTEIN;

ALZHEIMER DISEASE; BRAIN FUNCTION; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE COURSE; DRUG INHIBITION; GENE MUTATION; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; METABOLISM;

AGED; ALZHEIMER DISEASE; CARRIER PROTEINS; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; ZINC;

EID: 65549109871     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-0992     Document Type: Review

References (207)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60, 1119-1122.
2. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, TaylorJO(1989) Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262, 2551-2556.
3. Petersen RC, Morris JC (2003) Clinical features. In: Mild Cognitive Impairment, Petersen RC, ed., Oxford University, New York, pp. 15-39.
4. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J (2002) Natural history of mild cognitive impairment in older persons. Neurology 59, 198-205.
5. DeCarli C (2003) Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2, 15-21.
6. Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27, 570-575.
7. Klein WL (2002) Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41, 345-352.
8. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocam-pal long-term potentiation in vivo. Nature 416, 535-539.
9. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al. (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977.
10. St. George-Hyslop PH (1994) The molecular genetics of Alzheimer's disease. In: Alzheimer's disease, Terry RD, Katzman RBick LL, ed., Raven Press, New York, pp. 345-352.
11. Bertram L, Hiltunen M, Parkinson M, Ingelsson M, Lange C, Ramasamy K, Mullin K, Menon R, Sampson AJ, Hsiao MY, Elliott KJ, Velicelebi G, Moscarillo T, Hyman BT, Wagner SL, Becker KD, Blacker D, Tanzi RE (2005) Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med 352, 884-894.
12. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE (2000) Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290, 2302-2303.
13. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG (2000) Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 290, 2303-2304.
14. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM (2000) Susceptibility locus for Alzheimer's disease on chromosome 10. Science 290, 2304-2305.
15. RogaevaE,MengY, Lee JH,Gu Y, Kawarai T,ZouF,Kataya-ma T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shiba-ta N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39, 168-177.
16. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
17. Mortimer JA, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Rocca WA, et al. (1991) Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 20 Suppl 2, S28-35.
18. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR (1996) Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 275, 528-532.
19. Snowdon DA, Greiner LH, Markesbery WR (2000) Linguistic ability in early life and the neuropathology of Alzheimer's disease and cerebrovascular disease. Findings from the Nun Study. Ann N Y Acad Sci 903, 34-38.
20. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145, 301-308.
21. Chan SL, Griffin WS, Mattson MP (1999) Evidence for caspase-mediated cleavage of AMPA receptor subunits in neuronal apoptosis and Alzheimer's disease. J Neurosci Res 57, 315-323.
22. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262.
23. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
24. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141-1145.
25. Kleineke JW, Brand IA (1997) Rapid changes in intracellular Zn2+ in rat hepatocytes. J Pharmacol Toxicol Methods 38, 181-187.
26. Merchant C, Tang MX, Albert S,Manly J, Stern Y, Mayeux R (1999) The influence of smoking on the risk of Alzheimer's disease. Neurology 52, 1408-1412.
27. McMahon RJ, Cousins RJ (1998) Regulation of the zinc transporter ZnT-1 by dietary zinc. Proc Natl Acad Sci U S A 95, 4841-4846.
28. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346, 476-483.
29. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I (2003) An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 163, 1524-1528.
30. St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, Myers RH, Feldman RG, Pollen D, Drachman D, et al. (1987) The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 235, 885-890.
31. Sommer B (2002) Alzheimer's disease and the amyloid cascade hypothesis: ten years on. Curr Opin Pharmacol 2, 87-92.
32. Markesbery WR, Ehmann WD (1994) Trace element alterations in Alzheimer's disease. In: Alzheimer's disease, Terry RD, Katzman R, ed., Raven Press, New York, pp.
33. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695.
34. Wallace DC (1992) Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 256, 628-632.
35. Prasad AS, Miale A, Jr., Farid Z, Sandstead HH, Schulert AR (1963) Zinc metabolism in patients with the syndrome of iron deficiency anemia, hepatosplenomegaly, dwarfism, and hypognadism. J Lab Clin Med 61, 537-549.
36. Bettger WJ, O'Dell BL (1981) A critical physiological role of zinc in the structure and function of biomembranes. Life Sci 28, 1425-1438.
37. Golden BE (1989) Zinc in cell division and tissue growth: Physiological aspects. In: Zinc in Human Biology, Mills CF, ed., Springer-Verlag, London, pp. 119-127.
38. Vallee BL, Falchuk KH (1993) The biochemical basis of zinc physiology. Physiol Rev 73, 79-118.
39. Frederickson CJ (1989) Neurobiology of zinc and zinc-containing neurons. Int Rev Neurobiol 31, 145-238.
40. Colvin RA, Fontaine CP, Laskowski M, Thomas D (2003) Zn2+ transporters and Zn2+ homeostasis in neurons. Eur J Pharmacol 479, 171-185.
41. Bittel D, Dalton T, Samson SL, Gedamu L, Andrews GK (1998) The DNA binding activity of metal response element-binding transcription factor-1 is activated in vivo and in vitro by zinc, but not by other transition metals. J Biol Chem 273, 7127-7133.
42. Dalton TP, Bittel D, Andrews GK (1997) Reversible activation of mouse metal response element-binding transcription factor 1 DNA binding involves zinc interaction with the zinc finger domain. Mol Cell Biol 17, 2781-2789.
43. Dalton TP, Li Q, Bittel D, Liang L, Andrews GK (1996) Ox-idative stress activates metal-responsive transcription factor-1 binding activity. Occupancy in vivo of metal response elements in the metallothionein-I gene promoter. J Biol Chem 271, 26233-26241.
44. HaaseH, Beyersmann D(2002) Intracellular zinc distribution and transport in C6 rat glioma cells. Biochem Biophys Res Commun 296, 923-928.
45. Korichneva I, Hoyos B, Chua R, Levi E, Hammerling U (2002) Zinc release from protein kinase C as the common event during activation by lipid second messenger or reactive oxygen. J Biol Chem 277, 44327-44331.
46. Mocchegiani E, Bertoni-Freddari C, Marcellini F, Malavolta M (2005) Brain, aging and neurodegeneration: role of zinc ion availability. Prog Neurobiol 75, 367-390.
47. An WL, Bjorkdahl C, Liu R, Cowburn RF, Winblad B, Pei JJ (2005) Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells. J Neurochem 92, 1104-1115.
48. Ilouz R, Kaidanovich O, Gurwitz D, Eldar-Finkelman H (2002) Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem Biophys Res Commun 295, 102-106.
49. DanscherG,HowellG,Perez-Clausell J, Hertel N(1985) The dithizone, Timm's sulphide silver and the selenium methods demonstrate a chelatable pool of zinc in CNS. A proton activation (PIXE) analysis of carbon tetrachloride extracts from rat brains and spinal cords intravitally treated with dithizone. Histochemistry 83, 419-422.
50. Frederickson CJ, Klitenick MA, Manton WI, Kirkpatrick JB (1983) Cytoarchitectonic distribution of zinc in the hippocampus of man and the rat. Brain Res 273, 335-339.
51. Haug FM (1967) Electron microscopical localization of the zinc in hippocampal mossy fibre synapses by a modified sulfide silver procedure. Histochemie 8, 355-368.
52. Perez-Clausell J, Danscher G (1986) Release of zinc sulphide accumulations into synaptic clefts after in vivo injection of sodium sulphide. Brain Res 362, 358-361.
53. Takeda A (2000) Movement of zinc and its functional significance in the brain. Brain Res Brain Res Rev 34, 137-148.
54. Ebadi M,Iversen PL, Hao R, Cerutis DR, Rojas P, Happe HK, Murrin LC, Pfeiffer RF (1995) Expression and regulation of brain metallothionein. Neurochem Int 27, 1-22.
55. Price D, Joshi JG (1982) Ferritin: a zinc detoxicant and a zinc ion donor. Proc Natl Acad Sci U S A 79, 3116-3119.
56. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Bal-raj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Ox-idative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767.
57. Lehmann HM, Brothwell BB, Volak LP, Bobilya DJ (2002) Zinc status influences zinc transport by porcine brain capillary endothelial cells. J Nutr 132, 2763-2768.
58. Danscher G, Jensen KB, Frederickson CJ, Kemp K, An-dreasen A, Juhl S, Stoltenberg M, Ravid R (1997) Increased amount of zinc in the hippocampus and amygdala of Alzheimer's diseased brains: a proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J Neurosci Methods 76, 53-59.
59. Frederickson CJ, Koh JY, Bush AI (2005) The neurobiology of zinc in health and disease. Nat Rev Neurosci 6, 449-462.
60. Williams RJP (1989) An introduction to the biochemistry of zinc. In: Zinc in Human Biology, Mills CF, ed., Springer-Verlag, London, pp. 15-31.
61. Assaf SY, Chung SH (1984) Release of endogenous Zn2+ from brain tissue during activity. Nature 308, 734-736.
62. Howell GA, Welch MG, FredericksonCJ(1984) Stimulation-induced uptake and release of zinc in hippocampal slices. Nature 308, 736-738.
63. Palmiter RD (1998) The elusive function of metallothioneins. Proc Natl Acad Sci U S A 95, 8428-8430.
64. Kagi JH, Schaffer A (1988) Biochemistry of metallothionein. Biochemistry 27, 8509-8515.
65. Vallee BL (1995) The function of metallothionein. Neurochem Int 27, 23-33.
66. Penkowa M, Nielsen H, Hidalgo J, Bernth N, Moos T (1999) Distribution of metallothionein I + II and vesicular zinc in the developing central nervous system: correlative study in the rat. J Comp Neurol 412, 303-318.
67. Atar D, Backx PH, Appel MM, Gao WD, Marban E (1995) Excitation- transcription coupling mediated by zinc influx through voltage-dependent calcium channels. J Biol Chem 270, 2473-2477.
68. Durnam DM, Palmiter RD (1981) Transcriptional regulation of the mouse metallothionein-I gene by heavy metals. J Biol Chem 256, 5712-5716.
69. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE (1994) Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265, 1464-1467.
70. Maret W, Vallee BL (1998) Thiolate ligands in metalloth-ionein confer redox activity on zinc clusters. Proc Natl Acad Sci U S A 95, 3478-3482.
71. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL (2003) Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42, 12749-12760.
72. Huang L, Kirschke CP, Zhang Y, Yu YY (2005) The ZIP7 gene (Slc39a7) encodes a zinc transporter involved in zinc homeostasis of the Golgi apparatus. J Biol Chem 280, 15456-15463.
73. Koh JY, Choi DW (1994) Zinc toxicity on cultured cortical neurons: involvement of N-methyl-D-aspartate receptors. Neuroscience 60, 1049-1057.
74. Jia Y, Jeng JM, Sensi SL, Weiss JH (2002) Zn2+ currents are mediated by calcium-permeable AMPA/kainate channels in cultured murine hippocampal neurones. J Physiol 543, 35-48.
75. Cheng C, Reynolds IJ (1998) Calcium-sensitive fluorescent dyes can report increases in intracellular free zinc concentration in cultured forebrain neurons. J Neurochem 71, 2401-2410.
76. Eide DJ (2006) Zinc transporters and the cellular trafficking of zinc. Biochim Biophys Acta 1763, 711-722.
77. Palmiter RD (1995) Constitutive expression of metallothionein-III (MT-III), but not MT-I, inhibits growth when cells become zinc deficient. Toxicol Appl Pharmacol 135, 139-146.
78. Andrews GK(2001) Cellular zinc sensors: MTF-1 regulation of gene expression. Biometals 14, 223-237.
79. Chowanadisai W, Kelleher SL, Lonnerdal B (2005) Zinc deficiency is associated with increased brain zinc import and LIV-1 expression and decreased ZnT-1 expression in neonatal rats. J Nutr 135, 1002-1007.
80. Lovell MA, Smith JL, Markesbery WR (2006) Elevated zinc transporter-6 in mild cognitive impairment, Alzheimer disease, and pick disease. J Neuropathol Exp Neurol 65, 489-498.
81. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR (1997) Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18, 457-461.
82. Williams TI, Lynn BC, Markesbery WR, Lovell MA (2006) Increased levels of 4-hydroxynonenal and acrolein, neuro-toxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 27, 1094-1099.
83. Lovell MA, Markesbery WR (2005) Ectopic expression of Musashi-1 in Alzheimer disease and Pick disease. J Neuropathol Exp Neurol 64, 675-680.
84. Nolte C, Gore A, Sekler I, Kresse W, Hershfinkel M, Hoffmann A, Kettenmann H, Moran A (2004) ZnT-1 expression in astroglial cells protects against zinc toxicity and slows the accumulation of intracellular zinc. GLIA 48, 145-155.
85. Segal D, Ohana E, Besser L,Hershfinkel M, Moran A, Sekler I (2004) A role for ZnT-1 in regulating cellular cation influx. Biochem Biophys Res Commun 323, 1145-1150.
86. Ohana E, Sekler I, Kaisman T, Kahn N, Cove J, Silverman WF, Amsterdam A,Hershfinkel M (2006) Silencing of ZnT-1 expression enhances heavy metal influx and toxicity. J Mol Med 84, 753-763.
87. Palmiter RD, Cole TB, Findley SD (1996) ZnT-2, a mammalian protein that confers resistance to zinc by facilitating vesicular sequestration. EMBO J 15, 1784-1791.
88. Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ (2002) Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 277, 48984-48992.
89. Friedlich AL, Lee JY, van Groen T, Cherny RA, Volitakis I, Cole TB, Palmiter RD, Koh JY, Bush AI (2004) Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer's disease. J Neurosci 24, 3453-3459.
90. Huang L, Gitschier J (1997) A novel gene involved in zinc transport is deficient in the lethal milk mouse. Nat Genet 17, 292-297.
91. Kelleher SL, Lonnerdal B (2002) Zinc transporters in the rat mammary gland respond to marginal zinc and vitamin A intakes during lactation. J Nutr 132, 3280-3285.
92. Liu X, Lovell MA, Lynn BC (2006) Detection and quantification of endogenous cyclic DNA adducts derived from trans-4-hydroxy-2-nonenal in human brain tissue by isotope dilution capillary liquid chromatography nanoelectrospray tandem mass spectrometry. Chem Res Toxicol 19, 710-718.
93. Kambe T, Yamaguchi-Iwai Y, Sasaki R, Nagao M (2004) Overview of mammalian zinc transporters. Cell Mol Life Sci 61, 49-68.
94. Huang L, Kirschke CP, Gitschier J (2002) Functional characterization of a novel mammalian zinc transporter, ZnT6. J Biol Chem 277, 26389-26395.
95. Smith JL, Xiong S, Markesbery WR, Lovell MA (2006) Altered expression of zinc transporters-4 and -6 in mild cognitive impairment, early and late Alzheimer's disease brain. Neuroscience 140, 879-888.
96. Kirschke CP, Huang L(2003) ZnT7, a novel mammalian zinc transporter, accumulates zinc in the Golgi apparatus. J Biol Chem 278, 4096-4102.
97. Rivlin AA, Chan YL, Wool IG (1999) The contribution of a zinc finger motif to the function of yeast ribosomal protein YL37a. J Mol Biol 294, 909-919.
98. Choi DW, Yokoyama M, Koh J (1988) Zinc neurotoxicity in cortical cell culture. Neuroscience 24, 67-79.
99. Duncan MW, Marini AM, Watters R, Kopin IJ, Markey SP (1992) Zinc, a neurotoxin to cultured neurons, contaminates cycad flour prepared by traditional guamanian methods. J Neurosci 12, 1523-1537.
100. Yokoyama M, Koh J, Choi DW (1986) Brief exposure to zinc is toxic to cortical neurons. Neurosci Lett 71, 351-355.
101. Chuah MI, Tennent R, Jacobs I (1995) Response of olfactory Schwann cells to intranasal zinc sulfate irrigation. J Neurosci Res 42, 470-478.
102. Cuajungco MP, Lees GJ (1996) Prevention of zinc neu-rotoxicity in vivo by N,N,N',N'-tetrakis (2-pyridylmethyl) ethylene-diamine (TPEN). Neuroreport 7, 1301-1304.
103. Koh JY, Suh SW, Gwag BJ,HeYY, HsuCY, ChoiDW(1996) The role of zinc in selective neuronal death after transient global cerebral ischemia. Science 272, 1013-1016.
104. Gaskin F, KressY (1977) Zinc ion-induced assembly of tubu-lin. J Biol Chem 252, 6918-6924.
105. ManevH,KharlamovE,UzT,MasonRP,CagnoliCM(1997) Characterization of zinc-induced neuronal death in primary cultures of rat cerebellar granule cells. Exp Neurol 146, 171-178.
106. Kim EY, Koh JY, Kim YH, Sohn S, Joe E, Gwag BJ (1999) Zn2+ entry produces oxidative neuronal necrosis in cortical cell cultures. Eur J Neurosci 11, 327-334.
107. Beaulieu C, Dyck R, Cynader M (1992) Enrichment of glutamate in zinc-containing terminals of the cat visual cortex. Neuroreport 3, 861-864.
108. Bramham CR, Torp R, Zhang N, Storm-Mathisen J, Ottersen OP (1990) Distribution of glutamate-like immunoreactivity in excitatory hippocampal pathways: a semiquantitative electron microscopic study in rats. Neuroscience 39, 405-417.
109. Kesslak JP, Frederickson CJ, Gage FH (1987) Quantification of hippocampal noradrenaline and zinc changes after selective cell destruction. Exp Brain Res 67, 77-84.
110. Stengaard-Pedersen K, Fredens K, Larsson LI (1983) Comparative localization of enkephalin and cholecystokinin im-munoreactivities and heavy metals inthe hippocampus. Brain Res 273, 81-96.
111. Freund WD, Reddig S (1994) AMPA/Zn(2+)-induced neu-rotoxicity in rat primary cortical cultures: involvement of L-type calcium channels. Brain Res 654, 257-264.
112. Koh JY, Choi DW (1987) Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Meth 20, 83-90.
113. Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, Lipton RB (1999) Screening for dementia with the memory impairment screen. Neurology 52, 231-238.
114. Shore D, Henkin RI, Nelson NR, Agarwal RP, Wyatt RJ (1984) Hair and serum copper, zinc, calcium, and magnesium concentrations in Alzheimer-type dementia. J Am Geriatr Soc 32, 892-895.
115. Yin HZ, Weiss JH (1995) Zn(2+) permeates Ca(2+) permeable AMPA/kainate channels and triggers selective neural injury. Neuroreport 6, 2553-2556.
116. Hunter FEJ, FordL(1955) Inactivation ofoxidative andphos-phorylative systems in mitochondria by preincubation with phosphate and other. J Biol Chem 216, 357-369.
117. Kleiner D, von Jagow G (1972) On the inhibition of mito-chondrial electron transport by Zn(2+) ions. FEBS Lett 20, 229-232.
118. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245.
119. Skhulachev VP, Christyakov VV, Jasaitis AA, Smirnova EG (1967) Inhibition of the respiratory chain by zinc ions. Biochem Biophys Res Commun 26, 1-6.
120. Yamaguchi M, Kura M, Okada S (1982) Role of zinc as an activator of mitochondrial function in rat liver. Biochem Pharmacol 31, 1289-1293.
121. Canzoniero LM, Turetsky DM, Choi DW (1999) Measurement of intracellular free zinc concentrations accompanying zinc-induced neuronal death. J Neurosci 19, RC31.
122. Krotkiewska B, Banas T (1992) Interaction of Zn2+ and Cu2+ ions with glyceraldehyde-3-phosphate dehydrogenase from bovine heart and rabbit muscle. Int J Biochem 24, 1501-1505.
123. Ho LH, Ratnaike RN, Zalewski PD (2000) Involvement of intracellular labile zinc in suppression of DEVD-caspase activity in human neuroblastoma cells. Biochem Biophys Res Commun 268, 148-154.
124. Fliss H, Menard M (1992) Oxidant-induced mobilization of zinc from metallothionein. Arch Biochem Biophys 293, 195-199.
125. Gabrielsson B,Robson T,Norris D,Chung SH (1986) Effects of divalent metal ions on the uptake of glutamate and GABA from synaptosomal fractions. Brain Res 384, 218-223.
126. Vandenberg RJ, Mitrovic AD, Johnston GA (1998) Molecular basis for differential inhibition of glutamate transporter subtypes by zinc ions. Mol Pharmacol 54, 189-196.
127. Eagle GR, Zombola RR, Himes RH (1983) Tubulin-zinc interactions: binding and polymerization studies. Biochemistry 22, 221-228.
128. Gaskin F, Kress Y, Brosnan C, Bornstein M (1978) Abnormal tubulin aggregates induced by zinc sulfate in organotypic cultures of nerve tissue. Neuroscience 3, 1117-1128.
129. Backstrom JR, Miller CA, Tokes ZA (1992) Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metal-loproteinases from the hippocampus. J Neurochem 58, 983-992.
130. Kress Y, Gaskin F, Brosnan CF, Levine S (1981) Effects of zinc on the cytoskeletal proteins in the central nervous system of the rat. Brain Res 220, 139-149.
131. Murakami K, Whiteley MK, Routtenberg A (1987) Regulation of protein kinase C activity by cooperative interaction of Zn2+ and Ca2+. J Biol Chem 262, 13902-13906.
132. Rubin H, Koide T (1973) Stimulation of DNA synthesis and 2-deoxy-D-glucose transport in chick embryo cultures by excessive metal concentrations and by a carcinogenic hydrocarbon. J Cell Physiol 81, 387-396.
133. Baudier J, Haglid K, Haiech J, Gerard D (1983) Zinc ion binding to human brain calcium binding proteins, calmod-ulin and S100b protein. Biochem Biophys Res Commun 114, 1138-1146.
134. Brewer GJ, Aster JC, Knutsen CA, Kruckeberg WC (1979) Zinc inhibition of calmodulin: a proposed molecular mechanism of zinc action on cellular functions. Am J Hematol 7, 53-60.
135. Tonder N, Johansen FF, Frederickson CJ, Zimmer J, Diemer NH (1990) Possible role of zinc in the selective degeneration of dentate hilar neurons after cerebral ischemia in the adult rat. Neurosci Lett 109, 247-252.
136. Zalewski PD, Forbes IJ, Seamark RF, Borlinghaus R, Betts WH, Lincoln SF, Ward AD (1994) Flux of intracellular labile zinc during apoptosis (gene-directed cell death) revealed by a specific chemical probe, Zinquin. Chem Biol 1, 153-161.
137. Burnet FM (1981) A possible role of zinc in the pathology of dementia. Lancet 1, 186-188.
138. Andrasi E, Nadasdi J, Molnar Z, Bezur L, Ernyei L (1990) Determination of main and trace element contents in human brain by NAA and ICP-AES methods. Biol Trace Elem Res 26-27, 691-698.
139. Andrasi E, Suhajda M, Saray I, Bezur L, Ernyei L, Reffy A (1993) Concentration of elements in human brain: glioblas-toma multiforme. Sci Total Environ 139-140, 399-402.
140. Corrigan FM, Reynolds GP, Ward NI (1993) Hippocampal tin, aluminum and zinc in Alzheimer's disease. Biometals 6, 149-154.
141. Deng QS, Turk GC, Brady DR, Smith QR (1994) Evaluation of brain element composition in Alzheimer's disease using inductively coupled plasma mass spectrometry. Neurobiol Aging S113, 464.
142. Cornett CR, Markesbery WR, Ehmann WD (1998) Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 19, 339-345.
143. Deibel MA, Ehmann WD, Markesbery WR (1996) Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci 143, 137-142.
144. Ehmann WD, Markesbery WR, Alauddin M, Hossain TI, Brubaker EH (1986) Brain trace elements in Alzheimer's disease. Neurotoxicology 7, 195-206.
145. Samudralwar DL, Diprete CC, Ni BF, Ehmann WD, Markes-bery WR (1995) Elemental imbalances in the olfactory pathway in Alzheimer's disease. J Neurol Sci 130, 139-145.
146. Wenstrup D, Ehmann WD, Markesbery WR (1990) Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains. Brain Res 533, 125-131.
147. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158, 47-52.
148. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, Beyreuther K, Tanzi RE, Masters CL, Bush AI (1999) Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem 274, 23223-23228.
149. Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J (2006) Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. J Struct Biol 155, 30-37.
150. Stoltenberg M, Bruhn M, Sondergaard C, Doering P, West MJ, Larsen A, Troncoso JC, Danscher G (2005) Immersion autometallographic tracing of zinc ions in Alzheimer beta-amyloid plaques. Histochem Cell Biol 123, 605-611.
151. Frederickson CJ, Suh SW, Silva D, Thompson RB (2000) Importance of zinc in the central nervous system: the zinc-containing neuron. J Nutr 130, 1471S-1483S.
152. Lee JY, Mook-Jung I, Koh JY (1999) Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J Neurosci 19, RC10.
153. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, Carey PR (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42, 2768-2773.
154. Haines A, Iliffe S, Morgan P, Dormandy T, Wood B (1991) Serum aluminium and zinc and other variables in patients with and without cognitive impairment in the community. Clin Chim Acta 198, 261-266.
155. Molina JA, Jimenez-Jimenez FJ, Aguilar MV, Meseguer I, Mateos-Vega CJ, Gonzalez-Munoz MJ, de Bustos F, Porta J, Orti-Pareja M, Zurdo M, Barrios E, Martinez-Para MC (1998) Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J Neural Transm 105, 479-488.
156. Jeandel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin F, Cuny G (1989) Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 35, 275-282.
157. Rulon LL, Robertson JD, Lovell MA, Deibel MA, Ehmann WD, Markesber WR (2000) Serum zinc levels and Alzheimer's disease. Biol Trace Elem Res 75, 79-85.
158. C. G, Martin T, Cacho J, Brenea MT (1999) Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 29, 637-642.
159. Dong J, Robertson JD, Markesbery WR, Lovell MA (2008) Serum zinc in the progression of Alzheimer's disease. J Alzheimers Dis 15, 443-450.
160. Basun H, Forssell LG, Wetterberg L, Winblad B (1991) Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J Neural Transm Park Dis Dement Sect 3, 231-258.
161. Gerhardsson L, Lundh T, Minthon L, Londos E (2008) Metal Concentrations in Plasma and Cerebrospinal Fluid in Patients with Alzheimer's Disease. Dement Geriatr Cogn Disord 25, 508-515.
162. Strozyk D, Launer LJ, Adlard PA, Cherny RA, Tsatsanis A, Volitakis I, Blennow K, Petrovitch H, White LR, Bush AI (2009) Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol Aging, in press.
163. Yang JP, Merin JP, Nakano T, Kato T, Kitade Y, Okamoto T (1995) Inhibition of the DNA-binding activity of NF-kappa B by gold compounds in vitro. FEBS Lett 361, 89-96.
164. Zabel U, Schreck R, Baeuerle PA (1991) DNA binding of purified transcription factor NF-kappa B.Affinity, specificity, Zn2+ dependence, and differential half-site recognition. J Biol Chem 266, 252-260.
165. Zeng J, Heuchel R, Schaffner W, Kagi JH (1991) Thionein (apometallothionein) can modulate DNA binding and transcription activation by zinc finger containing factor Sp1. FEBS Lett 279, 310-312.
166. Wilquet V, De Strooper B (2004) Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol 14, 582-588.
167. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G (1999) Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14, 419-427.
168. Andrasi E, Farkas E, Gawlik D, Rosick U, Bratter P (2000) Brain Iron and Zinc Contents of German Patients with Alzheimer Disease. J Alzheimers Dis 2, 17-26.
169. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537-540.
170. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Tre-anor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmem-brane aspartic protease BACE. Science 286, 735-741.
171. Calingasan NY, Uchida K, Gibson GE (1999) Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem 72, 751-756.
172. Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC, Hyman BT (2003) Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci 116, 3339-3346.
173. Koo EH, Squazzo SL (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 269, 17386-17389.
174. Sisodia SS, St George-Hyslop PH (2002) gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the prese-nilins fit in? Nat Rev Neurosci 3, 281-290.
175. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399, A23-31.
176. Bush AI, Multhaup G, Moir RD, Williamson TG, Small DH, Rumble B, Pollwein P, Beyreuther K, Masters CL (1993) A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. J Biol Chem 268, 16109-16112.
177. Bergeron C, Petrunka C, Weyer L (1996) Copper/zinc superoxide dismutase expression in the human central nervous system. Correlation with selective neuronal vulnerability. Am J Pathol 148, 273-279.
178. Bush AI, Atwood CS, Huang L (1996) Abnormal homeosta-sis of ph1 and zinc: the prelunde for cerebral Aβ amyloid formation. Eur Neuropsychopharmacol 6 (suppl 3), S2-4.
179. Bush AI, Pettingell WH, Paradis MD, Tanzi R (1995) Zinc and Alzheimer's disease. Science 268, 1921-1923.
180. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, Maggio JE (1993) Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 61, 1171-1174.
181. Clements A, Allsop D, Walsh DM, Williams CH (1996) Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease. J Neurochem 66, 740-747.
182. Esler WP, Stimson ER, Jennings JM, Ghilardi JR, Mantyh PW, Maggio JE (1996) Zinc-induced aggregation of human and rat beta-amyloid peptides in vitro. J Neurochem 66, 723-732.
183. Dong J, Shokes JE, Scott RA, Lynn DG (2006) Modulating amyloid self-assembly and fibril morphology with Zn(II). J Am Chem Soc 128, 3540-3542.
184. Butterfield DA (2003) Amyloid beta-peptide [1-42]-associated free radical-induced oxidative stress and neurode-generation in Alzheimer's disease brain: mechanisms and consequences. Curr Med Chem 10, 2651-2659.
185. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butter-field DA, Markesbery WR (2005) Evidence of increased ox-idative damage in subjects with mild cognitive impairment. Neurology 64, 1152-1156.
186. Yatin SM, Varadarajan S, Link CD, Butterfield DA (1999) In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol Aging 20, 325-330; discussion 339-342.
187. Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491-1495.
188. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293w, 1487-1491.
189. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the protea-some. Neuron 43, 321-332.
190. Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A 91, 12243-12247.
191. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13, 1676-1687.
192. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (1997) APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56, 965-973.
193. Moechars D, Lorent K, De Strooper B, Dewachter I, Van Leu-venF(1996) Expressioninbrain ofamyloidprecursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J 15, 1265-1274.
194. Mucke L, Yu GQ, McConlogue L, Rockenstein EM, Abraham CR, Masliah E (2000) Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. Am J Pathol 157, 2003-2010.
195. Kumar-Singh S, Dewachter I, Moechars D, Lubke U, De Jonghe C, Ceuterick C, Checler F, Naidu A, Cordell B, Cras P, Van Broeckhoven C, Van Leuven F (2000) Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. Neurobiol Dis 7, 9-22.
196. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22, 1858-1867.
197. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW (1991) In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563, 311-314.
198. Walsh DM, Lomakin A,Benedek GB, Condron MM, Teplow DB (1997) Amyloid beta-proteinfibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 272, 22364-22372.
199. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280, 17294-17300.
200. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95, 6448-6453.
201. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, ChromyB,Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924, 133-140.
202. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG (2004) Permeabilization of lipid bilay-ers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279, 46363-46366.
203. Bush AI (2003) The metallobiology of Alzheimer's disease. Trends Neurosci 26, 207-214.
204. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease trans-genic mice. Neuron 30, 665-676.
205. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mast-wyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60, 1685-1691.
206. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quino-line analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55.
207. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW, PBT2-201-EURO study group (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7, 779-786.